BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...receptor selectivity over wild-type FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18...
...Hongyu Liu Patents: 1 issued covering fusion polypeptides of IFNλ and methods of use Targets FGF18...
...and activator of transcription 2 Hongjiang Li, Staff Writer Prosit Sole Biotechnology Co. Ltd. Interleukin-29 (IL-29) (IFNL1) Interleukin-28B (IL-28B) (IFNL3) Fibroblast growth factor 18 (FGF18) Interferon...
BioCentury | Nov 9, 2017
Clinical News

Merck's sprifermin meets in Phase II for OA

...KGaA (Xetra:MRK), Darmstadt, Germany Product: Sprifermin (AS902330) Business: Autoimmune Molecular target: Fibroblast growth factor 18 (FGF18) Description: Recombinant human FGF18...
...in the medial and lateral compartments and safety Status: Phase II data Milestone: NA Allison Johnson AS902330 Sprifermin Merck KGaA Fibroblast growth factor 18 (FGF18) American...
BioCentury | Nov 6, 2017
Clinical News

Merck's sprifermin passes Phase II test in OA

...data with regulatory authorities to determine next steps. Sprifermin is a recombinant human fibroblast growth factor 18 (FGF18). Allison Johnson AS902330 Sprifermin Merck KGaA Fibroblast growth factor 18 (FGF18) American...
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Cancer

...samples and mice suggest inhibiting FGF18 signaling could help treat ovarian cancer. In patient samples, FGF18...
...overall survival. In a mouse xenograft model of ovarian cancer, small hairpin RNA knockdown of FGF18...
...significantly decreased tumor burden compared with vehicle (p=0.006). Next steps include assessing the relevance of FGF18...
BioCentury | Sep 24, 2012
Emerging Company Profile

Arcarios: Protecting chondrocytes

...'s Merck Serono S.A. unit also is pursuing disease-modifying therapeutics in OA. Merck Serono's sprifermin fibroblast growth factor 18 (FGF18)...
...promoting the chondrocytes to make more matrix proteins and by inhibiting inflammation. It seems that FGF18...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...a unit of Merck KGaA (Xetra:MRK). Led early and late development programs, including atacicept and FGF18...
BioCentury | Sep 25, 2006
Strategy

Midcap wake-up call

...malignancies. ZGEN also granted SEO exclusive worldwide rights to develop and commercialize products based on fibroblast growth factor-18 (FGF-18)...
BioCentury | Jan 30, 2006
Strategy

The inside story

...SEO exclusive worldwide rights to develop and commercialize products based on fibroblast growth factor 18 (FGF-18...
BioCentury | Jan 30, 2006
Strategy

Serono chronicles

...research as well as exclusive worldwide rights to products based on fibroblast growth factor 18 (FGF-18...
BioCentury | Nov 14, 2005
Strategy

Pipeline stuffers

...research projects as well as exclusive worldwide rights to develop and commercialize products based on fibroblast growth factor-18 (FGF-18)...
Items per page:
1 - 10 of 18